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Introduction
Health technology assessment to determine relative cost-
effectiveness has been in operation in the UK since 1999.
Although Scotland has its own separate and independent pro-
cesses for assessing drugs and health technologies, the main
agency undertaking these activities is the National Institute for
Health and Clinical Excellence (NICE), an independent organi-
zation responsible for providing national guidance on promoting
good health and preventing and treating ill health. Premised on a
ﬁxed budget set by the Treasury, NICE was not founded to save
money, but rather to make the best use of the money available, to
eliminate inequalities in access to care, and to promote best
practices through the development of clinical guidelines. As a
result, the past decade has realized a buildup of infrastructure
and the development of systematic processes that have facilitated
the engagement of governments with the ﬁndings of the research
community such that active knowledge transfer is affecting the
decisions of all types of government agencies in the health ﬁeld.
NICE Activities
Importantly, NICE does not report through the Department of
Health, but advises the National Health Service directly. That is,
it advises directly those statutory bodies responsible for purchas-
ing and providing care. Because of the implications for spending,
the decisions of NICE may be used to justify future changes to
health-care budgets through the working of regular spending
reviews by the Treasury.
NICE is organized around four programs:
1. Technology Assessment Program—assesses the effectiveness
and cost-effectiveness of drugs and devices (diagnostics
about to be added).
2. Public Health Program—assesses the effectiveness and cost-
effectiveness of public health interventions (includes educa-
tional initiatives targeted at improving health outcomes).
3. Interventional Procedures Program—assesses the effective-
ness (but not cost-effectiveness) of surgical procedures,
interventional diagnostics, etc.
4. Guidelines Program—development of best practice guide-
lines (based on technology assessment when necessary and
taking intermittent cognizance of costs).
In addition to these four programs, there is also a research
arm and an implementation arm. Only aspects of the Technology
Assessment Program are discussed here.
Technology Assessment within NICE
Processes
The Technology Assessment Program was the ﬁrst program to be
initiated and covers both drugs and devices, although the major-
ity of appraisals to date have been of drugs. Some older and some
new (but not all) drugs have been evaluated by this program.
Historically, the review, synthesis of evidence, and economic
modeling of the technology under appraisal has always been
undertaken by NICE, which outsourced the work to one of seven
university Assessment Teams in a process now known as a “Mul-
tiple Technology Appraisal.” Drug companies were invited to
submit a drug value dossier that was one component of the
analysis and review of evidence relating to the effectiveness and
cost-effectiveness of the drug that was conducted by the commis-
sioned team. The university teams produced high quality publi-
cations on technologies and methods as a result of these activities
and the work was attractive to the groups concerned.
Working in conjunction with the Assessment Team, NICE
developed the pertinent questions about the drug that were to be
addressed within the context of existing technologies, a process
known as scoping. Scoping deﬁned the nature of the decision
problem to be considered and the comparisons to be included
through extensive dialog between NICE and the drug companies.
A set of clinical or patient guidelines or a review of patient ﬂow
under the current standard of care was often a typical starting
point for the discussion, with the key questions being how the
new technology would ﬁt in to the existing patient ﬂow, and what
the key comparators were within the existing system. Although
drug companies were able to input into the process of deﬁning
the decision questions, NICE was ultimately responsible for
ensuring the assessment was comprehensive and unbiased.
Once the scope was deﬁned, the Assessment Teams were then
responsible for producing the ﬁnal drug assessment documenta-
tion. This documentation then formed the basis for The
Appraisal Committee to reach a decision on whether the drug
was to be supported (and therefore reimbursed) within the
National Health Service via a three-stage process of preliminary
decision, consultation, and ﬁnal decision (plus the possibility of
appeal by interested parties). Of note, this approach meant that
the burden of proof that a drug was or was not cost-effective lay
with NICE rather than with the drug companies themselves.
Despite some concerns that the assessment process was not
transparent enough and inevitable press criticisms, by interna-
tional standards the process is very transparent. All reports,
comments, responses, and the basis for decision are published.
Indeed, it appears the reports are very widely read, with about 4
million hits on the reports on the website per year with many
hundreds of thousands of downloads, approximately half of
which are in North America. In fact, NICE has earned a good
reputation with stakeholders because of the perceived robustness
and transparency of its processes.
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Decisions
On examining the history of decisions, the majority of new
devices and new drugs that have been appraised have been sup-
ported by NICE to some degree. However, most usually, the
recommendation is more restrictive than the label. In general,
NICE will further deﬁne the circumstances in which the use of
the technology is appropriately cost effective; for example, by
specifying its use in particular patient groups, or in speciﬁed
situations.
Politics
Health care is overwhelmingly tax-ﬁnanced in the UK and the
constraints of a ﬁxed budget means that in some cases, the
decisions made by NICE are highly contentious. Not surprisingly,
this makes NICE vulnerable to political, media, and lobbyist
pressures. For example, recently, in response to parliamentary
pressure, NICE adopted policy changes to accommodate access
to some very expensive end-of-life drugs targeted at prolonging
the life of cancer patients by a few months. Subsequently,
however, the House of Commons Health Select Committee prof-
fered harsh criticism of the changes. Given the divergent interests
of the stakeholders, which include government, local Commis-
sioners of Health Services, drug companies, and the public, it
would seem inevitable that NICE will be subject to constant
criticism. However, on the positive side, as a conduit, NICE has
brought to the fore a very public discussion about the appropri-
ate threshold of cost-effectiveness for medical interventions.
Timeliness and the Introduction of Single
Technology Appraisal (STA)
Although NICE had achieved much credibility during its ﬁrst 5
years of operations, by 2005, both parts of the drug industry
and some politicians identiﬁed slow NICE procedures to be
signiﬁcantly contributing to slowing access to new drugs
(despite by far the biggest contribution to tardiness in NICE
pronouncing on new drugs being delay by Health Ministers in
deciding to refer the drug for consideration). The Institute was
required to develop faster systems. In response, NICE intro-
duced a shortened appraisal process known as STA, whereby a
company with a new drug or a new device is invited to make a
submission to NICE, which is then evaluated close to the time
of licensing. The highly structured and methodologically guided
submissions are now sent to university-based review teams for
commentary and critique. Unlike the earlier system, which con-
tinues in parallel, the burden of proof that a new drug or device
is cost-effective lies with the manufacturer, who must present
the case supporting the effectiveness and cost-effectiveness of the
technology? This allows NICE to reject technologies, rather
than look for evidence to support their use, if the case is not
satisfactorily made, or, alternatively, to make limited recommen-
dations such as for research use only, or a recommendation with
evidence development.
The adoption of STAs has speeded the assessment process so
that NICE is performing more evaluations and expects to be
reviewing all new drugs close to the time of launch in the near
future. However, although the process itself is faster, it appears
that the use of STAs has in fact reduced the proportion of
approvals. Furthermore, and of some concern, universities that
provided analytical services in the past are much less interested in
providing review services because reviews do not easily lead to
quality publications. This resulted in some universities reducing
their commitment or withdrawing their expertise altogether.
Impact
It is clear that the results of NICE appraisals have a signiﬁcant
impact on product sales ﬁgures; if a drug or intervention is not
recommended by NICE, for the most part, it will not be market-
able in the UK. On the other hand, in part because local budgets
have to accommodate new expenditures, a recommendation
from NICE does not guarantee that a technology will be imme-
diately adopted. Furthermore, it has become apparent that in
some cases, technologies were never adopted despite a recom-
mendation from NICE. As a consequence, in recent years, NICE
has concentrated more on implementation, and it is now man-
datory that local commissioners must show evidence of at least
plans for implementation of interventions that have been recom-
mended by NICE within 3 months of the guidance being issued.
Although difﬁcult to prove cause and effect, it is widely
believed that NICE appraisal has increased the uptake of a
number of effective drugs in several disease areas including
cancer, asthma, and coronary heart disease.
Closing Remarks
It is noteworthy that NICE appears to have produced a quite
remarkable and rather sophisticated awareness among health-
care staff and the general public, of the issues in allocating health
resources. This has led to a surprisingly large number of people
engaging in the debate around the cost-effectiveness threshold
that should be adopted. It may well be that this legacy of involve-
ment is the essential element in our achieving successful decision-
making about which health technologies we can afford.
Question Period
Audience Question: Here in the US, we have signiﬁcant
numbers of pharmacoeconomists and university-based pro-
grams. When you talk about the buildup of infrastructure
to facilitate the appraisal system, speciﬁcally, what kind of
infrastructure are you talking about?
Author: My understanding is that currently the US does not
have a decision-making strategy based around cost-
effectiveness. So, it is not just a matter of having capacity in
numbers of pharmacoeconomists and analysts, but it may
be that some different kinds of skills will be necessary if you
are going to try to address questions of cost-effectiveness.
Audience Question: If ensuring the best treatments were
being applied across the UK rather than cost-effectiveness
was initially the motivator for NICE, is cost containment
now taking priority?
Author: Although, of course, cost containment is always
important, NICE was not expected to produce cost savings.
However with ﬁxed budgets, implementation of NICE rec-
ommendations means that something else is displaced. Ulti-
mately, it is the value of what is displaced that determines
the threshold of cost-effectiveness. NICE therefore must
ensure that their recommendations are better value than
that which gets displaced.
Audience Question: My impression is that in the UK cost-
effectiveness is more accepted as a policy tool or technique
than it might be in Canada or the US. Could you comment
on why that is?
Author: Well, I think it’s certainly true that it’s more
accepted; we have very centralized budgetary systems that
make it quite clear to people that there are ﬁxed budgets and
this draws attention to the fact that cost-effectiveness
matters.
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